37 results found
Misra S, Mathieu C, 2018, Are newer insulin analogues better for people with Type 1 diabetes ?, Diabet Med
Achieving optimal blood glucose control in Type 1 diabetes is a delicate balance between ensuring tight glycaemic control and achieving this without the expense of hypoglycaemia and weight gain, two major factors impacting quality of life. This is a real challenge for people with Type 1 diabetes and underpins many of the struggles they face in self-managing on a day-to-day basis. The main goals of insulin delivery are to try to simulate the physiology of β-cell insulin secretion as closely as possible and to overcome the challenges of peripheral insulin administration by achieving rapidity of onset with mealtime insulins and stability of the glucose-lowering effects of long-acting insulins. Since the early days of human insulin use, there have been many developments in insulin formulations that aim to achieve these goals as much as possible, thus contributing to better glycaemic control whilst minimizing hypoglycaemia. In the present review we discuss the currently available insulin analogues and the challenges of achieving glucose control using current analogues in those on multiple daily injections, and appraise the evidence base for newer-generation insulin analogues, such as insulin degludec, glargine U300, faster-acting insulin aspart and BioChaperone lispro. We also highlight new insulins in development and unmet needs in people with Type 1 diabetes.
Misra S, Owen KR, 2018, Genetics of Monogenic Diabetes: Present Clinical Challenges, CURRENT DIABETES REPORTS, Vol: 18, ISSN: 1534-4827
Huddy JR, Ni M, Misra S, et al., 2018, Development of the Point-of-Care Key Evidence Tool (POCKET): a checklist for multi-dimensional evidence generation in point-of-care tests., Clin Chem Lab Med
Background This study aimed to develop the Point-of-Care Key Evidence Tool (POCKET); a multi-dimensional checklist to guide the evaluation of point-of-care tests (POCTs) incorporating validity, utility, usability, cost-effectiveness and patient experience. The motivation for this was to improve the efficiency of evidence generation in POCTs and reduce the lead-time for the adoption of novel POCTs. Methods A mixed qualitative and quantitative approach was applied. Following a literature search, a three round Delphi process was undertaken incorporating a semi-structured interview study and two questionnaire rounds. Participants included clinicians, laboratory personnel, commissioners, regulators (including members of National Institute for Health and Care Excellence [NICE] committees), patients, industry representatives and methodologists. Qualitative data were analysed based on grounded theory. The final tool was revised at an expert stakeholder workshop. Results Forty-three participants were interviewed within the semi-structured interview study, 32 participated in the questionnaire rounds and nine stakeholders attended the expert workshop. The final version of the POCKET checklist contains 65 different evidence requirements grouped into seven themes. Face validity, content validity and usability has been demonstrated. There exists a shortfall in the evidence that industry and research methodologists believe should be generated regarding POCTs and what is actually required by policy and decision makers to promote implementation into current healthcare pathways. Conclusions This study has led to the development of POCKET, a checklist for evidence generation and synthesis in POCTs. This aims to guide industry and researchers to the evidence that is required by decision makers to facilitate POCT adoption so that the benefits they can bring to patients can be effectively realised.
Misra S, Vedovato N, Cliff E, et al., 2018, Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment, DIABETIC MEDICINE, Vol: 35, Pages: 1291-1296, ISSN: 0742-3071
Hill NE, Deighton K, Matu J, et al., 2018, Continuous Glucose Monitoring at High AltitudeEffects on Glucose Homeostasis, MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, Vol: 50, Pages: 1679-1686, ISSN: 0195-9131
Bravis V, Kaur A, Walkey HC, et al., 2018, Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort, BMJ OPEN, Vol: 8, ISSN: 2044-6055
Srivanichakorn W, Godsland IF, Thomson H, et al., 2017, Fasting plasma glucose and variation in cardiometabolic risk factors in people with high-risk HbA1c-defined prediabetes: A cross-sectional multiethnic study, DIABETES RESEARCH AND CLINICAL PRACTICE, Vol: 134, Pages: 183-190, ISSN: 0168-8227
Misra S, 2017, Pancreatic autoantibodies: who to test and how to interpret the results, PRACTICAL DIABETES, Vol: 34, ISSN: 2047-2897
Walkey HC, Kaur A, Bravis V, et al., 2017, Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study, BMJ OPEN, Vol: 7, ISSN: 2044-6055
Aakre KM, Oosterhuis WP, Misra S, et al., 2017, Could accreditation bodies facilitate the implementation of medical guidelines in laboratories?, CLINICAL CHEMISTRY AND LABORATORY MEDICINE, Vol: 55, Pages: 806-808, ISSN: 1434-6621
Kaur A, Walkey H, Godsland IF, et al., 2017, Characteristics Associated with Diabetic Ketoacidosis in Children and Adults Newly Diagnosed with Type 1 Diabetes: Data from the After Diabetes Diagnosis Research Support System (ADDRESS-2) Cohort, 77th Scientific Sessions of the American-Diabetes-Association, Publisher: AMER DIABETES ASSOC, Pages: A467-A467, ISSN: 0012-1797
Misra S, Kaur A, Walkey H, et al., 2017, The Extent of Diabetes Misclassification One Year after a Diagnosis of Type 1 Diabetes: Data from the After Diabetes Diagnosis Research Support System (ADDRESS-2) Cohort, 77th Scientific Sessions of the American-Diabetes-Association, Publisher: AMER DIABETES ASSOC, Pages: A411-A412, ISSN: 0012-1797
Walkey HC, Kaur A, Godsland IF, et al., 2017, Clinical Presentation and Islet Autoantibody Status in a UK Multi-ethnic Cohort of Children and Adults with New-Onset Type 1 Diabetes-The After Diabetes Diagnosis Research Support System-2 (ADDRESS-2), 77th Scientific Sessions of the American-Diabetes-Association, Publisher: AMER DIABETES ASSOC, Pages: A467-A468, ISSN: 0012-1797
Misra S, Godsland I, Lupak L, et al., 2017, Predictors of C-Peptide in a Young-Onset Diabetes UK Multiethnic Cohort: Results from the MY DIABETES Study, 77th Scientific Sessions of the American-Diabetes-Association, Publisher: AMER DIABETES ASSOC, Pages: A421-A421, ISSN: 0012-1797
Misra S, Colclough K, Halleron K, et al., 2017, Type 1 diabetes phenotype in white and South Asian people with young onset diabetes in the UK: results from the MY DIABETES study, Spring Meeting on Clinician Scientists in Training, Publisher: ELSEVIER SCIENCE INC, Pages: 69-69, ISSN: 0140-6736
Misra S, Shields B, Colclough K, et al., 2016, South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people, DIABETOLOGIA, Vol: 59, Pages: 2262-2265, ISSN: 0012-186X
, 2016, Validation and regulation of point of care devices for medical applications, Medical Biosensors for Point of Care (POC) Applications, Pages: 27-44, ISBN: 9780081000786
© 2017 Elsevier Ltd All rights reserved. Point of care test (POCT) devices for medical applications require validation and regulation before they can be implemented into clinical practice. Undertaking method validation of devices ensures that their performance meets pre-specified analytical criteria and is a requirement assessed by accreditation bodies. Verifying these criteria also assesses real-world performance of analysers by end users and uncovers potential bias or variability in performance. Clinical validation of POCT devices defines the clinical need and assesses the effect of introducing the device into clinical pathways as well as demonstrating performance in a specific clinical context. Taken together these two stages of evaluation ensure that devices perform to an acceptable quality standard and, if undertaken appropriately, further provide evidence of clinical effectiveness. In this chapter, we review the features of method validation, which involves an analytical and clinical component and the regulation of POCT devices whilst also discussing the key considerations when implementing these devices for medical applications.
Barth JH, Misra S, Aakre KM, et al., 2016, Why are clinical practice guidelines not followed?, CLINICAL CHEMISTRY AND LABORATORY MEDICINE, Vol: 54, Pages: 1133-1139, ISSN: 1434-6621
Misra S, Hassanali N, Smith C, et al., 2016, A Homozygous Loss of Function HNF1A Variant Resulting in Sulfonylurea-Responsive Early-Onset Diabetes, 76th Scientific Sessions of the American-Diabetes-Association, Publisher: AMER DIABETES ASSOC, Pages: A418-A418, ISSN: 0012-1797
Misra S, Oliver N, 2015, Response to Rosival: Pathophysiology of diabetic ketoacidosis, DIABETIC MEDICINE, Vol: 32, Pages: 1527-1528, ISSN: 0742-3071
Misra S, Oliver NS, 2015, Diabetic ketoacidosis in adults, BMJ-BRITISH MEDICAL JOURNAL, Vol: 351, ISSN: 1756-1833
Misra S, Moberg-Aakre K, Langlois M, et al., 2015, How Useful are Laboratory Practice Guidelines?, EJIFCC, Vol: 26, Pages: 190-196, ISSN: 1650-3414
Clinical practice guidelines (CPGs) relating to laboratory diagnostic testing are increasingly produced with the aim of standardizing practice and improving patient care based on the best available evidence. However, the production of a CPG is merely the first step in the process of getting evidence into practice, to be undertaken by laboratories and other stakeholders. This process should evaluate the information provided in the guidelines on laboratory tests, devise a strategy for implementing the CPG or the laboratory aspects of the CPG and finally, once implemented, assess the impact of the CPG on clinical practice, patient outcomes and costs of care. The purpose of CPG evaluation by the laboratory is to determine whether sufficient information is provided on the particular test recommended. CPGs may not always be written with the involvement of a laboratory specialist and this underlies the paucity of relevant information in some national guidelines. When laboratory specialists are involved, CPGs can provide practical information which supports local laboratories as well as clinicians in the implementation and appropriate use of recommendations. Implementation of CPGs is an often neglected area that needs attention and thought. There are many barriers to successful implementation, which may vary at local level. These need to be identified early if CPGs are to be successfully adhered to. The effectiveness of CPGs also needs to be audited using process and health outcome indicators. Clinical audit is an effective tool for assessing adherence to recommendations and for measuring the impact and success of the CPG.
El-Laboudi A, Misra S, Martineau M, et al., 2015, INTENTIONAL LARGE INSULIN OVERDOSE CAPTURED ON A CONTINUOUS GLUCOSE MONITOR: A NOVEL CASE REPORT, DIABETES TECHNOLOGY & THERAPEUTICS, Vol: 17, Pages: A75-A76, ISSN: 1520-9156
Brouwers MCGJ, Ham JC, Wisse E, et al., 2015, Elevated Lactate Levels in Patients With Poorly Regulated Type 1 Diabetes and Glycogenic Hepatopathy: A New Feature of Mauriac Syndrome, DIABETES CARE, Vol: 38, Pages: E11-E12, ISSN: 0149-5992
Misra S, Oliver NS, 2015, Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis, DIABETIC MEDICINE, Vol: 32, Pages: 14-23, ISSN: 0742-3071
Tan TM, Salem V, Troke RC, et al., 2014, Combination of Peptide YY3-36 with GLP-1(7-36) amide Causes an Increase in First-Phase Insulin Secretion after IV Glucose, JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Vol: 99, Pages: E2317-E2324, ISSN: 0021-972X
Aakre KM, Langlois MR, Barth JH, et al., 2014, The quality of laboratory aspects of troponin testing in clinical practice guidelines and consensus documents needs to be improved, CLINICA CHIMICA ACTA, Vol: 437, Pages: 58-61, ISSN: 0009-8981
Misra S, Barth JH, 2014, How good is the evidence base for test selection in clinical guidelines?, CLINICA CHIMICA ACTA, Vol: 432, Pages: 27-32, ISSN: 0009-8981
Jayasena CN, Comninos AN, Veldhuis JD, et al., 2013, A single injection of kisspeptin-54 temporarily increases luteinizing hormone pulsatility in healthy women, CLINICAL ENDOCRINOLOGY, Vol: 79, Pages: 558-563, ISSN: 0300-0664
Misra S, Barth JH, 2013, Guidelines are written, but are they followed?, ANNALS OF CLINICAL BIOCHEMISTRY, Vol: 50, Pages: 400-402, ISSN: 0004-5632
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.